Gene Therapy Deal Benchmarks in Neurology
Market Analysis
Gene Therapy therapies in neurology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 gene therapy asset in neurology is $331M, with total deal values reaching $3.0B. Development milestones average $874M, while regulatory milestones contribute $953M.
The neurology gene therapy landscape is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones, reflecting the risk-reward profile at the Phase 2 stage.
Royalty rates for gene therapy neurology deals range from 12.3% to 19.7% at the base tier, with tiered escalation reaching 16.3%-23.7% on blockbuster sales. Commercial milestones averaging $821M further reward successful market penetration.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the typical upfront for a gene therapy neurology licensing deal?
What is the total deal value for gene therapy neurology transactions?
What royalty rates are standard for gene therapy deals in neurology?
How are milestones structured in gene therapy neurology deals?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.